PMID- 34835247
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211130
IS  - 2076-393X (Print)
IS  - 2076-393X (Electronic)
IS  - 2076-393X (Linking)
VI  - 9
IP  - 11
DP  - 2021 Nov 12
TI  - Anti-IAPP Monoclonal Antibody Improves Clinical Symptoms in a Mouse Model of Type 
      2 Diabetes.
LID - 10.3390/vaccines9111316 [doi]
LID - 1316
AB  - Type 2 Diabetes Mellitus (T2DM) is a chronic progressive disease, defined by 
      insulin resistance and insufficient insulin secretion to maintain normoglycemia. 
      Amyloidogenic aggregates are a hallmark of T2DM patients; they are cytotoxic for 
      the insulin producing beta-cells, and cause inflammasome-dependent secretion of 
      IL-1beta. To avoid the associated beta-cell loss and inflammation in advanced stage 
      T2DM, we developed a novel monoclonal therapy targeting the major component of 
      aggregates, islet amyloid polypeptide (IAPP). The here described monoclonal 
      antibody (mAb) m81, specific for oligomeric and fibrils, but not for soluble free 
      IAPP, is able to prevent oligomer growth and aggregate formation in vitro, and 
      blocks islet inflammation and disease progression in vivo. Collectively, our data 
      show that blocking fibril formation and prevention of new amyloidogenic 
      aggregates by monoclonal antibody therapy may be a potential therapy for T2DM.
FAU - Vogt, Anne-Cathrine S
AU  - Vogt AS
AD  - Department of Rheumatology and Immunology (RI), University Hospital, 3010 Bern, 
      Switzerland.
AD  - Department for BioMedical Research (DBMR), University of Bern, 3008 Bern, 
      Switzerland.
FAU - Roesti, Elisa S
AU  - Roesti ES
AD  - Department of Rheumatology and Immunology (RI), University Hospital, 3010 Bern, 
      Switzerland.
AD  - Department for BioMedical Research (DBMR), University of Bern, 3008 Bern, 
      Switzerland.
FAU - Mohsen, Mona O
AU  - Mohsen MO
AD  - Department of Rheumatology and Immunology (RI), University Hospital, 3010 Bern, 
      Switzerland.
AD  - Department for BioMedical Research (DBMR), University of Bern, 3008 Bern, 
      Switzerland.
FAU - Leonchiks, Ainars
AU  - Leonchiks A
AUID- ORCID: 0000-0001-5907-4969
AD  - Latvian Biomedical Research and Study Centre, Ratsupites 1 k1, LV-1067 Riga, 
      Latvia.
FAU - Vogel, Monique
AU  - Vogel M
AD  - Department of Rheumatology and Immunology (RI), University Hospital, 3010 Bern, 
      Switzerland.
AD  - Department for BioMedical Research (DBMR), University of Bern, 3008 Bern, 
      Switzerland.
FAU - Bachmann, Martin F
AU  - Bachmann MF
AUID- ORCID: 0000-0003-4370-2099
AD  - Department of Rheumatology and Immunology (RI), University Hospital, 3010 Bern, 
      Switzerland.
AD  - Department for BioMedical Research (DBMR), University of Bern, 3008 Bern, 
      Switzerland.
AD  - Centre for Cellular and Molecular Physiology (CCMP), Nuffield Department of 
      Medicine, The Jenner Institute, University of Oxford, Oxford OX3 7BN, UK.
LA  - eng
PT  - Journal Article
DEP - 20211112
PL  - Switzerland
TA  - Vaccines (Basel)
JT  - Vaccines
JID - 101629355
PMC - PMC8622146
OTO - NOTNLM
OT  - amylin
OT  - amyloid
OT  - islet amyloid polypeptide (IAPP)
OT  - monoclonal antibody (mAb)
OT  - type 2 diabetes (T2DM)
COIS- M.F. Bachmann declares to be involved in several companies developing vaccines 
      for various diseases. The other authors declare no further conflict of interest.
EDAT- 2021/11/28 06:00
MHDA- 2021/11/28 06:01
PMCR- 2021/11/12
CRDT- 2021/11/27 01:27
PHST- 2021/09/18 00:00 [received]
PHST- 2021/11/05 00:00 [revised]
PHST- 2021/11/08 00:00 [accepted]
PHST- 2021/11/27 01:27 [entrez]
PHST- 2021/11/28 06:00 [pubmed]
PHST- 2021/11/28 06:01 [medline]
PHST- 2021/11/12 00:00 [pmc-release]
AID - vaccines9111316 [pii]
AID - vaccines-09-01316 [pii]
AID - 10.3390/vaccines9111316 [doi]
PST - epublish
SO  - Vaccines (Basel). 2021 Nov 12;9(11):1316. doi: 10.3390/vaccines9111316.